Joseph Akers Net Worth

The estimated Net Worth of Joseph A Akers is at least $1.2 Milhão dollars as of 21 September 2018. Mr. Akers owns over 200,000 units of Titan Pharmaceuticals, (de) stock worth over $1,199,190 and over the last 8 years he sold TTNP stock worth over $0. In addition, he makes $0 as Independent Director at Titan Pharmaceuticals, (de).

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Akers TTNP stock SEC Form 4 insiders trading

Joseph has made over 1 trades of the Titan Pharmaceuticals, (de) stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of TTNP stock worth $50,000 on 21 September 2018.

The largest trade he's ever made was buying 200,000 units of Titan Pharmaceuticals, (de) stock on 21 September 2018 worth over $50,000. On average, Joseph trades about 40,000 units every 0 days since 2017. As of 21 September 2018 he still owns at least 213,000 units of Titan Pharmaceuticals, (de) stock.

You can see the complete history of Mr. Akers stock trades at the bottom of the page.

Joseph Akers biography

Joseph A. Akers serves as Independent Director of the Company. He was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley. Based on Mr. Akers’ extensive management experience in the pharmaceutical industry, particularly in the areas of administration and finance, our Board believes that Mr. Akers has the appropriate set of skills to serve as a member of the Board.

How old is Joseph Akers?

Joseph Akers is 74, he's been the Independent Director of Titan Pharmaceuticals, (de) since 2014. There are 2 older and 5 younger executives at Titan Pharmaceuticals, (de). The oldest executive at Titan Pharmaceuticals, Inc. (de) is M. David MacFarlane, 79, who is the Independent Director.

What's Joseph Akers's mailing address?

Joseph's mailing address filed with the SEC is 102 W. GLENHAVEN DRIVE, , PHOENIX, AZ, 85045.

Insiders trading at Titan Pharmaceuticals, (de)

Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over $4,610,001 worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth $2,558,794 . The most active insiders traders include David E.Activist Investing ..., James R Mcnab, eMarc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of $2,815,253. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth $4,610,001.

What does Titan Pharmaceuticals, (de) do?

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Complete history of Mr. Akers stock trades at Titan Pharmaceuticals, (de)

Titan Pharmaceuticals, (de) executives and stock owners

Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include:

• Marc Rubin,
  Executive Chairman of the Board, Chief Executive Officer
• Katherine DeVarney,
  President, Chief Operating Officer, Chief Scientific Officer, Director
• Dr. Katherine L. Beebe-DeVarney Ph.D.,
  Pres, COO & Director
• Dr. Marc Rubin M.D.,
  Exec. Chairman & Principal Exec. Officer
• Stephen Kilmer,
  Investor Relations
• James McNab,
  Independent Director
• M. David MacFarlane,
  Independent Director
• Joseph Akers,
  Independent Director
• Scott Smith,
  Independent Director
• Joe Schrei,
  Exec. Director of Commercial Operations
• Jennifer Kiernan,
  Exec. Assistant to CEO & Investor Communications Coordinator
• Mike Fritz,
  National Sales Director
• Brian E. Crowley,
  VP of Fin.
• Dane Hallberg,
  See Remarks
• Eurelio M Cavalier,
  Director
• Sunil Bhonsle,
  President and CEO
• Choon Hau Choong,
  10% owner
• Rajinder Kumar,
  Director
• Matthew Charles Mc Murdo,
  Director
• David Natan,
  Director
• Peter Louis Chasey,
  Director
• Federico Seghi Recli,
  Director
• Avraham Ben Tzvi,
  Director
• David E. Lazar,
  Chief Executive Officer
• Eric Howard Greenberg,
  Director
• Katherine Beebe,
  President and COO
• David E.Activist Investing ...,
  Chief Executive Officer